David M Margolis
Overview
Explore the profile of David M Margolis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
10265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turner A, Bashore F, Falcinelli S, Fox J, Keller A, Fenton A, et al.
J Virol
. 2025 Mar;
:e0177724.
PMID: 40067013
Importance: Multiple factors and pathways contribute to the maintenance of HIV latency, including bromo and extra-terminal domain (BET) family member BRD4. While small molecule inhibitors of the BET family result...
2.
Wang Y, Gornalusse G, Siegel D, Barbehenn A, Hoh R, Martin J, et al.
bioRxiv
. 2025 Feb;
PMID: 39990376
Despite antiretroviral therapy (ART), people with HIV (PWH) on ART experience higher rates of morbidity and mortality vs. age-matched HIV negative controls, which may be driven by chronic inflammation due...
3.
Council O, Tyers L, Moeser M, Sondgeroth A, Spielvogel E, Richardson B, et al.
J Virol
. 2024 Dec;
99(2):e0097924.
PMID: 39723838
Previous studies have shown that the majority of long-lived cells harboring persistent HIV-1 proviral genomes originates from viruses circulating in the year prior to antiretroviral therapy (ART) initiation, but a...
4.
McKellar M, Keys J, Filiatreau L, McGee K, Kuruc J, Ferrari G, et al.
J Antimicrob Chemother
. 2024 Nov;
80(1):169-174.
PMID: 39504491
Background: Antiretroviral therapy (ART) is recommended for all individuals with HIV infection, including those with acute HIV-1 infection (AHI). While recommendations are similar to those for chronic infection, efficacy data...
5.
Semenova L, Wang Y, Falcinelli S, Archin N, Cooper-Volkheimer A, Margolis D, et al.
Elife
. 2024 Sep;
13.
PMID: 39250423
Understanding the interplay between the HIV reservoir and the host immune system may yield insights into HIV persistence during antiretroviral therapy (ART) and inform strategies for a cure. Here, we...
6.
Ashokkumar M, Hafer T, Felton A, Archin N, Margolis D, Emerman M, et al.
bioRxiv
. 2024 Aug;
PMID: 39211204
Author Summary: HIV latency is a major obstacle for the eradication of HIV. However, molecular mechanisms that restrict proviral expression during therapy are not well understood. Identification of host cell...
7.
Ling L, Kim M, Soper A, Kovarova M, Spagnuolo R, Begum N, et al.
mBio
. 2024 Aug;
15(9):e0163224.
PMID: 39136440
The HIV reservoir is more dynamic than previously thought with around 70% of the latent reservoir originating from viruses circulating within 1 year of the initiation of antiretroviral therapy (ART)....
8.
Margolis D
Infect Dis Clin North Am
. 2024 Jul;
38(3):487-497.
PMID: 38969530
Therapies to eradicate human immunodeficiency virus (HIV) infection, sparing lifelong antiviral therapy, are a still-distant goal. But significant advances have been made to reverse HIV latency while antiretroviral therapy (ART)...
9.
Van Gulck E, Pardons M, Nijs E, Verheyen N, Dockx K, Van Den Eynde C, et al.
Antimicrob Agents Chemother
. 2024 Jul;
68(8):e0081924.
PMID: 38953623
No abstract available.
10.
Ashokkumar M, Mei W, Peterson J, Harigaya Y, Murdoch D, Margolis D, et al.
Genomics Proteomics Bioinformatics
. 2024 Jun;
22(1).
PMID: 38902848
Despite the success of antiretroviral therapy, human immunodeficiency virus (HIV) cannot be cured because of a reservoir of latently infected cells that evades therapy. To understand the mechanisms of HIV...